{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-017191","form_type":"8-K","ticker":"OLED","cik":"0001005284","company_name":"UNIVERSAL DISPLAY CORP PA","filed_at":"2023-05-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.548674+00:00","generated_at":"2026-06-15T23:54:58.730483+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"UDC Q1 revenue down 13% to $130.5M; acquires Merck KGaA OLED patents for $66M","bullets":["Q1 2023 revenue of $130.5M vs $150.5M YoY; net income $39.8M ($0.83 diluted EPS) vs $50.0M ($1.05).","Reaffirms FY 2023 revenue guidance of $550M to $600M; declares Q2 dividend of $0.35/share payable June 30.","Acquired Merck KGaA's phosphorescent OLED emitter patent portfolio for $66M cash; over 550 patents across 172 families.","Multi-year collaboration with Merck KGaA for advanced PHOLED stacks using UDC's green/yellow emitters and Merck's transport/host materials."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-017191","json":"https://secwatch.observer/filing/0000950170-23-017191.json","markdown":"https://secwatch.observer/filing/0000950170-23-017191.md","text":"https://secwatch.observer/filing/0000950170-23-017191.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1005284/000095017023017191/0000950170-23-017191-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1005284/000095017023017191/oled-20230503.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T23:54:58.730483+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"877f0dd564fd32f421b9f934f4dff441a5dacba2","claim":"UNIVERSAL DISPLAY CORP PA reported the first quarter ended March 31, 2023 results: revenue $130.5 million, net income $39.8 million, EPS $0.83 per diluted share. Guidance reaffirmed.","evidence_excerpt":"new multi-year collaboration agreement with Merck KGaA, Darmstadt, Germany.” Financial Highlights for the First Quarter of 2023 • Total revenue in the first quarter of 2023 was $130.5 million as compared to $150.5 million in the first quarter of 2022. As we have previously noted, the near-term weakness in the overall global market economy continues to have an impact","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1005284/000095017023017191/0000950170-23-017191-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2023"},{"label":"Revenue","value":"$130.5 million"},{"label":"Net income","value":"$39.8 million"},{"label":"EPS","value":"$0.83 per diluted share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}